Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes

被引:29
|
作者
Engelen, Suzanne E. [1 ]
van der Graaf, Yolanda [5 ]
Stam-Slob, Manon C. [1 ]
Grobbee, Diederick E. [5 ]
Cramer, Maarten J. [2 ]
Kappelle, L. Jaap [3 ]
de Borst, Gert J. [4 ]
Visseren, Frank L. J. [1 ]
Westerink, Jan [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Cardiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Weg 100, NL-3584 CG Utrecht, Netherlands
关键词
Type; 2; diabetes; Cardiovascular disease; Interventions; PERIPHERAL ARTERIAL-DISEASE; SIROLIMUS-ELUTING STENTS; OUTCOMES; THROMBOSIS; MELLITUS; RISK; MORTALITY;
D O I
10.1016/j.ijcard.2017.07.081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Diabetes mellitus is associated with an increased risk for cardiovascular morbidity and mortality. The vascular burden in terms of incidence of cardiovascular events (CVE) and vascular interventions is however poorly quantified. In this study we evaluated the incidence rates of CVE and vascular interventions in patients with type 2 diabetes (T2DM) with and without cardiovascular disease (CVD) in comparison to patients without type 2 diabetes. Research design and methods: In a cohort of 9.808 high-risk patients with and without cardiovascular disease and type 2 diabetes originated from the ongoing, single-center prospective SMART (Second Manifestations of ARTerial disease) cohort, the number and incidence rates of CVE and interventions were calculated. The incidence rates were adjusted for confounders using Poisson regression models. CVE were defined as vascular death, stroke and myocardial infarction (MI). Interventions were defined as percutaneous coronary intervention, coronary artery bypass grafting, percutaneous transluminal angioplasty or stenting of the peripheral arteries and amputation. Results: Patients with T2DM and CVD had a 4-fold higher incidence rate of CVE and a 8-fold higher incidence rate of vascular interventions compared to high-risk patients without T2DM and CVD after adjusting for confounders. The incidence rate for the composite of non-fatal MI, non-fatal stroke and vascular death was 5.8 per 1000 person-years in patients without T2DM or CVD at baseline, 15.2 per 1000 person-years in patients with T2DM but without CVD at baseline, 26.0 per 1000 person-years in patients without T2DM but with CVD and 40.7 per 1000 person-years in patients with both T2DM and CVD at baseline. A similar increasing incidence rate was seen for all vascular interventions from patients without T2DM or CVD to patients with both T2DM and CVD. Conclusions: Patients with type 2 diabetes or CVD are subject to an increased incidence of cardiovascular events and interventions compared to high-risk patients without type 2 diabetes or vascular disease. Patients with type 2 diabetes and CVD have the highest incidence of new cardiovascular diseases and vascular interventions when compared to patients without type 2 diabetes and CVD. These results underline the need for optimal risk factor treatment as well as the need for new prevention and treatment strategies in this very high risk population. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [41] Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease
    Pantalone, Kevin M.
    Misra-Hebert, Anita D.
    Hobbs, Todd M.
    Ji, Xinge
    Kong, Sheldon X.
    Milinovich, Alex
    Weng, Wayne
    Bauman, Janine
    Ganguly, Rahul
    Burguera, Bartolome
    Kattan, Michael W.
    Zimmerman, Robert S.
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [42] Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes
    Muszynska-Oglaza, Alicja
    Zarzycka-Lindner, Grazyna
    Olejniczak, Henryka
    Polaszewska-Muszynska, Miroslawa
    Junik, Roman
    ENDOKRYNOLOGIA POLSKA, 2017, 68 (06) : 652 - +
  • [43] Meat intake and incidence of cardiovascular disease in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS)
    Horikawa, Chika
    Kamada, Chiemi
    Tanaka, Shiro
    Tanaka, Sachiko
    Araki, Atsushi
    Ito, Hideki
    Matsunaga, Satoshi
    Fujihara, Kazuya
    Yoshimura, Yukio
    Ohashi, Yasuo
    Akanuma, Yasuo
    Sone, Hirohito
    EUROPEAN JOURNAL OF NUTRITION, 2019, 58 (01) : 281 - 290
  • [44] Management of Cardiovascular Risk among Moroccan Patients with Type 2 Diabetes: A Cross-Sectional Study
    Moumen, Amal
    Zraidi, Mohamed
    Derrou, Sara
    Benabdelfedil, Yousra
    El Guendouz, Faycal
    CLINICAL DIABETOLOGY, 2023, 12 (03): : 171 - 178
  • [45] Effect of hyperlipidemia on the incidence of cardio-cerebrovascular events in patients with type 2 diabetes
    Fan, Dabei
    Li, Li
    Li, Zhizhen
    Zhang, Ying
    Ma, Xiaojun
    Wu, Lina
    Qin, Guijun
    LIPIDS IN HEALTH AND DISEASE, 2018, 17
  • [46] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Prattichizzo, Francesco
    La Sala, Lucia
    Ryden, Lars
    Marx, Nikolaus
    Ferrini, Marc
    Valensi, Paul
    Ceriello, Antonio
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
  • [47] Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
    Paul, Sanjoy K.
    Klein, Kerenaftali
    Thorsted, Brian L.
    Wolden, Michael L.
    Khunti, Kamlesh
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [48] Blood adiponectin levels are not associated with risk of cardiovascular events in patients with type 2 diabetes
    Jeon, Ja Young
    Ha, Kyoung Hwa
    Han, Seung Jin
    Kim, Hae Jin
    Lee, Kwan-Woo
    Kim, Dae Jung
    DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (06) : 571 - 575
  • [49] Impact of Successive Glycated Hemoglobin Level on Cardiovascular Events in Patients With Type 2 Diabetes
    Morimoto, Takeshi
    Ogawa, Hisao
    Sakuma, Mio
    Okada, Sadanori
    Soejima, Hirofumi
    Ohtorii, Makiko
    Nakayama, Masafumi
    Uemura, Shiro
    Kanauchi, Masao
    Doi, Naofumi
    Jinnouchi, Hideaki
    Sugiyama, Seigo
    Waki, Masako
    Kawano, Takahiro
    Saito, Yoshihiko
    CIRCULATION, 2013, 128 (22)
  • [50] Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
    Charytan, David M.
    Solomon, Scott D.
    Ivanovich, Peter
    Remuzzi, Giuseppe
    Cooper, Mark E.
    McGill, Janet B.
    Parving, Hans-Henrik
    Parfrey, Patrick
    Singh, Ajay K.
    Burdmann, Emmanuel A.
    Levey, Andrew S.
    Eckardt, Kai-Uwe
    McMurray, John J. V.
    Weinrauch, Larry A.
    Liu, Jiankang
    Claggett, Brian
    Lewis, Eldrin F.
    Pfeffer, Marc A.
    DIABETES OBESITY & METABOLISM, 2019, 21 (05) : 1199 - 1208